Avadel Pharmaceuticals Overview
- Year Founded
-
1990
- Status
-
Public
- Employees
-
188
- Stock Symbol
-
AVDL
- Investments
-
3
- Share Price
-
$8.31
- (As of Wednesday Closing)
Avadel Pharmaceuticals General Information
Description
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Contact Information
Website
www.avadel.comCorporate Office
- 16640 Chesterfield Grove Road
- Suite 200
- Chesterfield, MO 63005
- United States
Corporate Office
- 16640 Chesterfield Grove Road
- Suite 200
- Chesterfield, MO 63005
- United States
Avadel Pharmaceuticals Stock Performance
As of 23-Apr-2025, Avadel Pharmaceuticals’s stock price is $8.31. Its current market cap is $803M with 96.6M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.31 | $8.27 | $6.38 - $19.09 | $803M | 96.6M | 1.19M | -$0.51 |
Avadel Pharmaceuticals Financials Summary
As of 31-Dec-2024, Avadel Pharmaceuticals has a trailing 12-month revenue of $169M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 948,894 | 948,894 | 1,138,960 | 474,136 |
| Revenue | 169,117 | 169,117 | 27,963 | 0 |
| EBITDA | (35,568) | (35,568) | (149,125) | (97,604) |
| Net Income | (48,832) | (48,832) | (160,276) | (137,464) |
| Total Assets | 164,236 | 164,236 | 164,698 | 132,785 |
| Total Debt | 1,704 | 1,704 | 2,624 | 131,022 |
Avadel Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Avadel Pharmaceuticals Comparisons
Industry
Financing
Details
Avadel Pharmaceuticals Competitors (18)
One of Avadel Pharmaceuticals’s 18 competitors is Halozyme Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Halozyme Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Histogen | Formerly VC-backed | San Ramon, CA | ||||
| Santhera Pharmaceuticals | Private Debt Financed | Pratteln, Switzerland | ||||
| Lisata Therapeutics | Corporate Backed or Acquired | Basking Ridge, NJ | ||||
| Gyre Therapeutics | Formerly VC-backed | San Diego, CA |
Avadel Pharmaceuticals Patents
Avadel Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20120308614-A1 | Composition for the controlled release of buprenorphine | Inactive | 31-May-2011 | ||
| FR-2975912-B1 | Controlled release composition of buprenorphine | Inactive | 30-May-2011 | ||
| FR-2975912-A1 | Controlled release composition of buprenorphine | Active | 30-May-2011 | ||
| FR-2975301-B1 | Composition comprising an alpha interferon | Inactive | 20-May-2011 | ||
| US-20120294832-A1 | Composition comprising interferon alpha | Inactive | 20-May-2011 | A61K38/212 |
Avadel Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Avadel Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Avadel Pharmaceuticals Investments & Acquisitions (3)
Avadel Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Serenity Pharmaceuticals (Noctiva) for . The deal was made on 01-Sep-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Serenity Pharmaceuticals (Noctiva) | 01-Sep-2017 | Corporate Asset Purchase | Buildings and Property | ||
| FSC Pediatrics | 05-Feb-2016 | Merger/Acquisition | Medical Supplies | ||
| Eclat Pharmaceuticals | 13-Mar-2012 | Merger/Acquisition | Pharmaceuticals |
Avadel Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated March, 07, 2024
29.97 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Pharmaceuticals
Subindustry
of 430
Rank
Percentile
Avadel Pharmaceuticals FAQs
-
When was Avadel Pharmaceuticals founded?
Avadel Pharmaceuticals was founded in 1990.
-
Where is Avadel Pharmaceuticals headquartered?
Avadel Pharmaceuticals is headquartered in Chesterfield, MO.
-
What is the size of Avadel Pharmaceuticals?
Avadel Pharmaceuticals has 188 total employees.
-
What industry is Avadel Pharmaceuticals in?
Avadel Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Avadel Pharmaceuticals a private or public company?
Avadel Pharmaceuticals is a Public company.
-
What is Avadel Pharmaceuticals’s stock symbol?
The ticker symbol for Avadel Pharmaceuticals is AVDL.
-
What is the current stock price of Avadel Pharmaceuticals?
As of 23-Apr-2025 the stock price of Avadel Pharmaceuticals is $8.31.
-
What is the current market cap of Avadel Pharmaceuticals?
The current market capitalization of Avadel Pharmaceuticals is $803M.
-
What is Avadel Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Avadel Pharmaceuticals is $169M.
-
Who are Avadel Pharmaceuticals’s competitors?
Halozyme Therapeutics, Histogen, Santhera Pharmaceuticals, Lisata Therapeutics, and Gyre Therapeutics are some of the 18 competitors of Avadel Pharmaceuticals.
-
What is Avadel Pharmaceuticals’s annual earnings per share (EPS)?
Avadel Pharmaceuticals’s EPS for 12 months was -$0.51.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
